Wang Zhongyu, Guo Fengli, Fu Guiming, Zhao Zewei, Kang Ning, Hou Xiukun, Zheng Xiangqian
Department of Thyroid and Neck Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Department of Thyroid and Breast Surgery, Binzhou Medical University Hospital, Binzhou, China.
Front Oncol. 2024 Jun 6;14:1379420. doi: 10.3389/fonc.2024.1379420. eCollection 2024.
Aurora kinase A (AURKA) and tumor-infiltrating lymphocytes (TILs) are both known to play an essential role in tumorigenesis. However, the expression and prognostic value of the AURKA and TILs in medullary thyroid carcinoma (MTC) have not yet been investigated.
Surgical specimens and clinical data of 137 patients diagnosed with MTC were collected. AURKA expression and TILs infiltration were quantified by immunohistochemistry and hematoxylin-eosin staining. Subsequently, the prognostic value of AURKA expression and TIL infiltration in MTC was evaluated.
AURKA was highly expressed in patients with multifocal tumor, cervical lymph node metastasis, and an advanced TNM stage, indicating a high probability of recurrence. AURKA further exhibited a positive correlation with TILs (R = 0.44, < 0.001). High expression of AURKA combined with a low numbers of TILs (AURKA/TILs) was identified as an independent prognostic factor for biochemical recurrence (odds ratio: 4.57, 95% confidence interval: 1.54-14.66, < 0.01) and recurrence-free survival (hazard ratio: 3.64, 95% confidence interval: 1.52-8.71, < 0.001). The combination of AURKA and TILs apparently improves the prognostic value for biochemical recurrence (area under the curve: 0.751) and structural recurrence (area under the curve: 0.836) of MTC. Notably, AURKA/TILs demonstrated a high value for prediction of distant or unresectable locoregional recurrence, with an overall accuracy of 86.9%.
AURKA is associated with the MTC malignancy. The combination of AURKA/TILs was identified as novel independent prognostic marker in MTC, predicting incurable disease recurrence with high accuracy.
已知极光激酶A(AURKA)和肿瘤浸润淋巴细胞(TILs)在肿瘤发生中均起重要作用。然而,AURKA和TILs在甲状腺髓样癌(MTC)中的表达及预后价值尚未得到研究。
收集137例确诊为MTC患者的手术标本及临床资料。通过免疫组织化学和苏木精-伊红染色对AURKA表达和TILs浸润进行定量分析。随后,评估AURKA表达和TIL浸润在MTC中的预后价值。
AURKA在多灶性肿瘤、颈部淋巴结转移及TNM分期较晚的患者中高表达,提示复发可能性高。AURKA与TILs呈正相关(R = 0.44,P < 0.001)。AURKA高表达联合TILs数量少(AURKA/TILs)被确定为生化复发(比值比:4.57,95%置信区间:1.54 - 14.66,P < 0.01)和无复发生存(风险比:3.64,95%置信区间:1.52 - 8.71,P < 0.001)的独立预后因素。AURKA和TILs的联合明显提高了MTC生化复发(曲线下面积:0.751)和结构复发(曲线下面积:0.836)的预后价值。值得注意的是,AURKA/TILs对远处或不可切除的局部区域复发具有较高的预测价值,总体准确率为86.9%。
AURKA与MTC恶性程度相关。AURKA/TILs联合被确定为MTC新的独立预后标志物,可高精度预测不可治愈疾病复发。